{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:54:26Z","timestamp":1777571666849,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["201603"],"award-info":[{"award-number":["201603"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1038\/s41375-024-02294-8","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T07:02:18Z","timestamp":1717225338000},"page":"1469-1473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitors in chronic lymphocytic leukaemia"],"prefix":"10.1038","volume":"38","author":[{"given":"Yingqi","family":"Shao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4226-9580","authenticated-orcid":false,"given":"Yang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"key":"2294_CR1","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41375-020-0852-7","volume":"34","author":"SA Parikh","year":"2020","unstructured":"Parikh SA, Gale RP, Kay NE. Chronic lymphocytic leukemia in 2020: a surfeit of riches? Leukemia. 2020;34:1979\u201383.","journal-title":"Leukemia"},{"key":"2294_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363.","journal-title":"Am J Hematol"},{"key":"2294_CR3","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol"},{"key":"2294_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"2294_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S0140-6736(02)07816-9","volume":"359","author":"KF Schulz","year":"2002","unstructured":"Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. Lancet. 2002;359:696\u2013700.","journal-title":"Lancet"},{"key":"2294_CR6","doi-asserted-by":"publisher","first-page":"E201","DOI":"10.1503\/cmaj.120744","volume":"185","author":"A Hr\u00f3bjartsson","year":"2013","unstructured":"Hr\u00f3bjartsson A, Thomsen ASS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. CMAJ. 2013;185:E201\u201311.","journal-title":"CMAJ"},{"key":"2294_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2023-174289","volume":"142","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst BF, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, et al. Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R\/R CLL\/SLL). Blood. 2023;142:202.","journal-title":"Blood"},{"key":"2294_CR8","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440\u201350.","journal-title":"Blood Adv"},{"key":"2294_CR9","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1200\/JCO.2022.40.16_suppl.7539","volume":"40","author":"JP Sharman","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik AP, Kamdar MK, Munir T, et al. Acalabrutinib \u00b1 obinutuzumab versus obinutuzumab + chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. J Clin Oncol. 2022;40:7539.","journal-title":"J Clin Oncol"},{"key":"2294_CR10","doi-asserted-by":"publisher","first-page":"e15364af","DOI":"10.1097\/01.HS9.0000969460.15364.af","volume":"7","author":"T Munir","year":"2023","unstructured":"Munir T, Shadman M, Robak T, Brown JR, Kahl B, Ghia P, et al. P639: Zanubrutinib (ZANU) vs bendamustine + RITUXIMAB (BR) in patients (PTS) with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma (cll\/sll): extended follow-up of the sequoia study. Hemasphere. 2023;7:e15364af.","journal-title":"Hemasphere"},{"key":"2294_CR11","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood.2019896688","volume":"133","author":"IE Ahn","year":"2019","unstructured":"Ahn IE, Basumallik N, Tian X, Soto S, Wiestner A. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood. 2019;133:2452\u20135.","journal-title":"Blood"},{"key":"2294_CR12","doi-asserted-by":"publisher","first-page":"e2313819","DOI":"10.1001\/jamanetworkopen.2023.13819","volume":"6","author":"MA Florez","year":"2023","unstructured":"Florez MA, Jaoude JA, Patel RR, Kouzy R, Lin TA, De B, et al. Incidence of primary end point changes among active cancer phase 3 randomized clinical trials. JAMA Netw Open. 2023;6:e2313819.","journal-title":"JAMA Netw Open"},{"key":"2294_CR13","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41409-020-01167-9","volume":"56","author":"RP Gale","year":"2021","unstructured":"Gale RP. Being certain even when you\u2019re wrong: heuristics and thin slicing in haematopoietic cell transplantation. Bone Marrow Transpl. 2021;56:1223\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2294_CR14","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf."},{"key":"2294_CR15","doi-asserted-by":"publisher","first-page":"e236498","DOI":"10.1001\/jamanetworkopen.2023.6498","volume":"6","author":"A Das","year":"2023","unstructured":"Das A, Lin TA, Lin C, Meirson T, McCaw ZR, Tian L, et al. Assessment of median and mean survival time in cancer clinical trials. JAMA Netw Open. 2023;6:e236498.","journal-title":"JAMA Netw Open"},{"key":"2294_CR16","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3747\/co.22.2119","volume":"22","author":"C Beauchemin","year":"2015","unstructured":"Beauchemin C, Johnston JB, Lapierre M\u00c8, Aissa F, Lachaine J. Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis. Curr Oncol. 2015;22:e148\u201356.","journal-title":"Curr Oncol"},{"key":"2294_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","volume":"153","author":"S Gilboa","year":"2021","unstructured":"Gilboa S, Pras Y, Mataraso A, Bomze D, Markel G, Meirson T. Informative censoring of surrogate end-point data in phase 3 oncology trials. Eur J Cancer. 2021;153:190\u2013202.","journal-title":"Eur J Cancer"},{"key":"2294_CR18","doi-asserted-by":"crossref","unstructured":"Woyach JA, Perez Burbano GE, Ruppert AS, Miller CR, Heerema NA, Zhao W, et al. Long-term follow-up from A041202 shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024; blood.2023021959.","DOI":"10.1182\/blood.2023021959"},{"key":"2294_CR19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:1278\u201391.","journal-title":"Lancet"},{"key":"2294_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","volume":"36","author":"JP Sharman","year":"2022","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia. Leukemia. 2022;36:1171\u20135.","journal-title":"Leukemia"},{"key":"2294_CR21","unstructured":"https:\/\/www.fda.gov\/files\/drugs\/published\/Multiple-Endpoints-in-Clinical-Trials-Guidance-for-Industry.pdf."},{"key":"2294_CR22","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1200\/JCO.23.00225","volume":"41","author":"M Merino","year":"2023","unstructured":"Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival. J Clin Oncol. 2023;41:2706\u201312.","journal-title":"J Clin Oncol"},{"key":"2294_CR23","doi-asserted-by":"publisher","first-page":"e78258de","DOI":"10.1097\/01.HS9.0000969484.78258.de","volume":"7","author":"P Ghia","year":"2023","unstructured":"Ghia P, Munir T, Burger J, Seymour J, Rogers K, Huang HH, et al. P645: ibrutinib for treatment of relapsed-refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison of 3 randomized phase 3 trials. Hemasphere. 2023;7:e78258de.","journal-title":"Hemasphere"},{"key":"2294_CR24","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.1158\/1078-0432.CCR-20-4912","volume":"27","author":"AK Amatya","year":"2021","unstructured":"Amatya AK, Fiero MH, Bloomquist EW, Sinha AK, Lemery SJ, Singh H, et al. Subgroup analyses in oncology trials: regulatory considerations and case examples. Clin Cancer Res. 2021;27:5753\u20136.","journal-title":"Clin Cancer Res"},{"key":"2294_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta5330","volume":"5","author":"ST Brookes","year":"2001","unstructured":"Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5:1\u201356.","journal-title":"Health Technol Assess"},{"key":"2294_CR26","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","volume":"192","author":"S Schandelmaier","year":"2020","unstructured":"Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020;192:E901\u2013E906.","journal-title":"CMAJ"},{"key":"2294_CR27","first-page":"3289","volume":"85","author":"H Haider","year":"2020","unstructured":"Haider H, Hoehn B, Davis S, Greiner R. Effective ways to build and evaluate individual survival distributions. J Mach Learn Res 2020;85:3289\u2013351.","journal-title":"J Mach Learn Res"},{"key":"2294_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/10428194.2021.1973672","volume":"63","author":"R Agius","year":"2022","unstructured":"Agius R, Parviz M, Niemann CU. Artificial intelligence models in chronic lymphocytic leukemia - recommendations toward state-of-the-art. Leuk Lymphoma. 2022;63:265\u201378.","journal-title":"Leuk Lymphoma"},{"key":"2294_CR29","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1038\/s41375-021-01419-7","volume":"35","author":"S Yang","year":"2021","unstructured":"Yang S, Kay NE, Shi M, Ossenkoppele G, Walter RB, Gale RP. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both? Leukemia. 2021;35:3364\u201370.","journal-title":"Leukemia"},{"key":"2294_CR30","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1200\/JCO.23.00619","volume":"41","author":"TJ Kipps","year":"2023","unstructured":"Kipps TJ. Challenging the value of minimal residual disease in predicting outcome of patients with chronic lymphocytic leukemia. J Clin Oncol. 2023;41:3676\u20138.","journal-title":"J Clin Oncol"},{"key":"2294_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112\u201320.","journal-title":"Blood"},{"key":"2294_CR32","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1182\/blood.2020010146","volume":"138","author":"XV Wang","year":"2021","unstructured":"Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021;138:2810\u201327.1.","journal-title":"Blood"},{"key":"2294_CR33","doi-asserted-by":"publisher","first-page":"e064430a","DOI":"10.1097\/01.HS9.0000967492.06443.0a","volume":"7","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. S145: venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized cll14 study. Hemasphere. 2023;7:e064430a.","journal-title":"Hemasphere"},{"key":"2294_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535\u201352.","journal-title":"Lancet Oncol"},{"key":"2294_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2020.09.031","volume":"141","author":"K Rosen","year":"2020","unstructured":"Rosen K, Prasad V, Chen EY. Censored patients in Kaplan-Meier plots of cancer drugs: an empirical analysis of data sharing. Eur J Cancer. 2020;141:152\u201361.","journal-title":"Eur J Cancer"},{"key":"2294_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114022","volume":"202","author":"V Lesan","year":"2024","unstructured":"Lesan V, Olivier T, Prasad V. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. Eur J Cancer. 2024;202:114022.","journal-title":"Eur J Cancer"},{"key":"2294_CR37","first-page":"1720","volume":"388","author":"Y Liang","year":"2023","unstructured":"Liang Y, Gale RP. Zanubrutinib in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1720.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02294-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02294-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02294-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:05:42Z","timestamp":1720706742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02294-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2294"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02294-8","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"25 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NEK is on the advisory boards of AbbVie, AstraZeneca, Beigene, Behring, Boehringer Ingelheim Pharmaceuticals, Inc., Dava Oncology, Janssen, Juno Therapeutics and Pharmacyclics. He is on the Data Safety Monitoring Committee for Agios Pharm, AstraZeneca, BMS\u2013Celgene and Dren Bio Janssen. He receives research funding from AbbVie, Acerta Pharma, BMS- Celgene, Genentech, Pharmacyclics, Sunesis and Vincerx. RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd. RPG is an Editor of <i>LEUKEMIA<\/i>.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}